Lung cancer doesn’t stop for a pandemic and neither do we!

ANNUAL REPORT
CONTENTS

Letter from the President and CEO ............... 2
LUNGevity By the Numbers ..................... 3
Covid-19 and Lung Cancer ....................... 4
Research ........................................... 5-7
Clinical Trial Transformation ..................... 8
Patient-focused Research ......................... 9
Precision Medicine Initiatives ................... 10-11
Public Policy ...................................... 12-13
Awareness ......................................... 14
Survivorship and Support ........................ 15
Education ........................................... 16
Recognition ....................................... 17
Building Our Community ........................ 18-19
Expanding Organizational Capabilities .......... 20
Board of Directors and Scientific Advisory Board .. inside back cover
2020 was an unprecedented year, with new challenges for many people, particularly those living with lung cancer. However, it was also a year of innovation and hope that pushed LUNGevity to adapt and re-imagine our programs to better serve the lung cancer community.
LETTER FROM THE PRESIDENT AND CEO

We are proud of all we accomplished this year, with the support, participation and generous funding from our donors, partners and constituents. The pandemic threw obstacles in our way, but LUNGevity was able to achieve more than we could ever have anticipated. We end the year with record fundraising, exciting and impactful new programs, our seventh 4-Star Charity Navigator rating, and a powerful reminder of what we can accomplish when a community comes together with a common goal.

LUNGevity research programs continued to innovate and move forward. Lung cancer doesn’t stop for a pandemic, and neither did we. In 2020, LUNGevity funded three Career Development Awards. We also funded three ALK Positive Lung Cancer Research Awards, in conjunction with the ALK Positive/LUNGevity patient group, and launched the EGFR Positive/LUNGevity Lung Cancer Research Award Program in partnership with the EGFR Resisters.

LUNGevity delivered relevant, timely information about the coronavirus through the COVID-19 and Lung Cancer website, with regular updates from the CDC and other experts on the coronavirus, Conversations with Healthcare Experts video series, and weekly COVID-19 newsletters.

The Breathe Easier Emergency Response Fund provided financial relief to many during the early months of the pandemic. Weekly virtual meetups, which grew from once a week to four times a week, continue to allow isolated people affected by lung cancer to receive valuable support services and important information as it becomes available.

We made steps towards a better understanding of the patient experience through the launch of Project PEER, a multi-year, international study. LUNGevity is collaborating with the FDA on this project, offering the agency real-world data about how members of our patient population, particularly those underrepresented in clinical trials, respond to therapies.

LUNGevity precision medicine initiatives made inroads into overcoming barriers to comprehensive biomarker testing, including convening a pan-cancer coalition to advocate for consistency in testing terminology.

Lung cancer advocates have a new way to make a difference with the launch of the online LUNGevity Action Network. By participating in a variety of public policy and awareness activities, our community can make meaningful changes for those affected by lung cancer.

LUNGevity continued its commitment to ensuring that all people, even the most vulnerable populations, have access to optimal care. The Health Equity Council, consisting of oncology researchers, community leaders, patient advocates, pharmaceutical company representatives, and healthcare providers from high-risk areas, was established to guide these important Foundation efforts. The Lung Cancer Scorecard graded states on Medicaid policies that impact access to screening and biomarker testing for optimal care. Finally, Project DIRECT aimed to understand the biomarker testing experience of underserved lung cancer patients, with the goal of developing patient-centric solutions to close gaps in testing and treatment.

Events went virtual, from our National Breathe Deep events and the first ever eRACE Lung Cancer to the International Lung Cancer Survivorship Conference, which served over 4,000 patients and caregivers from across the world. The virtual platform made our events more inclusive by including those who might otherwise have been unable to attend in person.

Thank you for your ongoing support. Together we will create a world where no one dies of lung cancer.

Sincerely,

Andrea Ferris
President and CEO
### LUNGEVITY FOUNDATION 2020 BY THE NUMBERS

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registrants for Annual Scientific and Clinical Roundtables</td>
<td>189</td>
</tr>
<tr>
<td>New Research Grants in Partnership with ALK Positive Patient Group</td>
<td>3</td>
</tr>
<tr>
<td>Responders to First Lungevity Action Network Alert</td>
<td>1430</td>
</tr>
<tr>
<td>Translation Research Career Development Awards</td>
<td>3</td>
</tr>
<tr>
<td>Inhale for Life PSA Campaigns</td>
<td>2</td>
</tr>
<tr>
<td>Patient Force Abstracts Presented at International Conferences</td>
<td>18</td>
</tr>
<tr>
<td>Calls to the Lungevity Helpline</td>
<td>2875</td>
</tr>
<tr>
<td>Virtual International Lung Cancer Survivorship Conference</td>
<td>1</td>
</tr>
<tr>
<td>New Board of Directors Members</td>
<td>4</td>
</tr>
<tr>
<td>Longitudinal Research Study with EGFR Resisters</td>
<td>1</td>
</tr>
<tr>
<td>Virtual International Lung Cancer Survivorship Conference</td>
<td>5</td>
</tr>
<tr>
<td>Take Aim Stakeholder Meetings</td>
<td>2</td>
</tr>
<tr>
<td>New Scientific Advisory Board Members</td>
<td>2</td>
</tr>
<tr>
<td>(4th Consecutive) 4-Star Rating from Charity Navigator</td>
<td>7th</td>
</tr>
<tr>
<td>Breathe Deep Together Participants</td>
<td>1611</td>
</tr>
</tbody>
</table>
COVID-19 AND LUNG CANCER

From the start of the pandemic, LUNGevity has provided relevant, timely information about COVID-19 to our community. We are proud to serve our community during these unprecedented times.

LUNGevity WEBSITE COVID-19 INFORMATION

In early March of 2020, the sudden rise in COVID-19 cases in the US and the impending shelter-from-home rules across the country created an immediate need to inform people with lung cancer and their families on how to navigate the pandemic. By March 12, the COVID-19 and Lung Cancer dedicated section of the website was live, providing medically accurate and credible information about the virus as it became available.

Spanish Language COVID website
A COVID-19 and Lung Cancer site was created in Spanish, with translations of all documents and video transcripts on the English language site. Spanish subtitles were created for the expert videos. Over 140,600 visitors came to the sites through the end of the 2020 calendar year.

COVID AND POLICY

LUNGevity has been very involved in coalition activities surrounding the impact of COVID-19 on cancer patients. The All Cancers Congress coalition, which formed in 2019, met weekly throughout 2020 to discuss policy proposals and ways that we can act collectively to improve care for cancer patients during these times. Some of the areas that LUNGevity has engaged on are telemedicine, the need for ALL insurers to allow patients to receive 90-day supplies of oral therapies, oral parity (which requires health plans to ensure that patients being treated for cancer do not pay more for an oral medication than for one administered by IV), anti-discrimination/rationing, patient concerns about participating in clinical trials during the pandemic, and requests for financial relief to non-profit entities. The sign-on letters are posted on the policy section of the LUNGevity website as well as the LUNGevity COVID website.

IMPACT

The COVID-19 and Lung Cancer dedicated section of the LUNGevity website provides medically accurate and credible information about the virus as it became available.

Conversations with Experts videos in English, Spanish and Mandarin

COVID-19 FAQs

COVID-19 Glossary

Weekly joint COVID-19 updates with information from such sources as the CDC and WHO, with fellow lung cancer organizations including GO2 Foundation, the Lung Cancer Foundation of America, Lung Cancer Research Foundation and LungCAN

Help with medications (pharma industry updates)

Self-care for Patients and Caregivers – tips and videos on nutrition, exercise and mental health

COVID-19 Policy Initiatives

In addition to the website, LUNGevity has responded to the pandemic by:

Creating the Breathe Easier Emergency Response Fund, which provided financial relief to many during the early months of the pandemic.

Offering weekly Virtual Meetups that have allowed isolated people affected by lung cancer to connect virtually with their peers; we have expanded the program to accommodate the growing demand.

Sending out special update eblasts to keep our constituents informed of new videos, information and activities.
Despite the global health crisis, lung cancer research continued to move forward. Eleven new lung cancer treatment approaches were approved by the US FDA in 2020 alone. More new treatments mean more people living well with the disease. Research is key to these advances, and LUNGevity has not stopped funding scientific research during the pandemic.

**TRANSLATIONAL RESEARCH**
LUNGevity’s highly regarded translational research program is driving real change in the early detection and treatment of lung cancer. This year, LUNGevity continued funding our Stand Up 2 Cancer early detection award, and a new cohort of three Career Development Awards. We also funded three ALK Positive Lung Cancer Research Awards in conjunction with the ALK Positive patient group, and launched the EGFR-Positive Lung Cancer Research Award Program in partnership with patient group EGFR Resisters.

**SU2C Grants: Intercepting Lung Cancer**
Building on 10 years of investment in early detection, LUNGevity teamed up with Stand Up to Cancer (SU2C) and American Lung Association in 2017 to fund innovative research into the early detection of lung cancer. Today, this research project is making exceptional progress in helping us understand, diagnose and treat early-stage lung cancer.

**SU2C - LUNGevity Foundation - American Lung Association**

**A 4-YEAR LUNG CANCER INTERCEPTION DREAM TEAM AWARD**

**The Intercept Lung Cancer Through Immune, Imaging, & Molecular Evaluation (InTIME) Team**

Led by **Drs. Avrum Spira** and **Steven Dubinett**, the Dream Team is developing non-invasive diagnostic tools, such as nasal swabs, blood tests, and radiological imaging, to confirm whether lung abnormalities found on chest imaging are benign lung disease or lung cancer. To protect against recurrence of early-stage disease that has already been successfully treated with surgery, the research team is also developing new blood tests that will help identify patients at the earliest stages of recurrence, enabling timely interventions, such as immunotherapy.

The Dream Team has already made significant progress toward achieving these goals. They have characterized the immune cells surrounding premalignant lesions (PMLs) versus those which surround lung cancer tissue. They found that there are fewer T-cells (specialized cancer-killing immune cells) around the lung cancer tissue, suggesting that lung cancer, even in its earliest stage, figures out ways to escape recognition by the immune system. This knowledge will be central to the development of strategies to harness the immune system to control lung cancer in its early stages. In addition, the Dream Team has developed a non-invasive blood test that can detect circulating DNA (ctDNA — genetic material released from lung cancer cells) in the blood of lung cancer patients and predict whether a patient is likely to relapse after surgery for early-stage lung cancer.
RESEARCH

Career Development Awards
LUNGevity CDAs are awarded to early-career researchers whose proposals demonstrate potential for either detecting lung cancer early, when it is most treatable, or extending and improving the lives of lung cancer patients with new treatment options. The CDA program encourages the awardees to continue their development in lung cancer research to ensure a strong pipeline of dedicated lung cancer researchers. To date, LUNGevity has offered this award to 29 researchers.

The 2020 LUNGevity Career Development Award recipients are working in key areas of lung cancer research: one working to understand and prevent resistance to drugs targeting the KRAS mutation, and two seeking to develop novel strategies to enhance the benefits of immunotherapy — through combination with DNA damage response inhibitors, or with radiation.

Translational Research Awards in collaboration with ALK Positives patient oncogene group
In its second year, the ALK Positive Transformational Research Award program is being supported by ALK Positive — a group of 1,800+ ALK Positive patients and their caregivers in 42+ countries — to directly influence the direction of research that will, one day, save these patients’ lives. ALK Positives are partnering with LUNGevity because of the effectiveness of the organization’s robust translational research program. Together, we are awarding high-impact projects that seek to transform the future for patients affected by ALK-positive non-small cell lung cancer.

Three translational research awards were given that aim to understand how immunotherapy can be used for ALK-positive patients, a group that has not benefited from these therapies to date.

THE 9TH CLASS OF LUNGevity CAREER DEVELOPMENT AWARDS

Kathryn Arbour, MD
Memorial Sloan Kettering Cancer Center
Mechanisms of resistance to direct KRAS G12C inhibition.

Dr. Arbour’s study seeks to prevent resistance to a drug that targets the KRAS G12C mutation among NSCLC patients. She is the recipient of the Kristie Rolke Smith/LUNGevity Career Development Award, generously funded by the Rolke family in memory of their daughter, Kristie.

Carl Gay, MD, PhD
The University of Texas MD Anderson Cancer Center
SCLC molecular subtypes to predict targeted and immune therapy response.

Dr. Gay’s research aims to develop a new drug therapy combination and determine which patients are likely to benefit from it.

Sean Pitroda, MD
The University of Chicago
Predictive biomarkers of radio-immuno-therapeutic response in NSCLC.

Dr. Pitroda’s goal is to determine which patients are likely to benefit from an immunotherapy-radiation therapy combination.

ALK POSITIVE TRANSLATIONAL RESEARCH AWARDS

Phase 1 first-in-human clinical trial with a therapeutic ALK vaccine in patients with ALK+ NSCLC
Mark Awad, MD, PhD
Dana-Farber Cancer Institute

Overcoming bypass signaling to enhance clinical responses in ALK-positive lung cancer
Ibiayi Dagogo-Jack, MD
Massachusetts General Hospital

Overcoming ALK resistance with covalent cysteine-reactive inhibitors
A. John Iafrate, MD, PhD,
Massachusetts General Hospital

Two of the selected projects are clinical trials.
**IMPACT**

<table>
<thead>
<tr>
<th>Awardees</th>
<th>Publications</th>
<th>Longitudinal Research Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>75</td>
<td>1</td>
</tr>
</tbody>
</table>

$27.1$ Million

More than $27.1 Million has been generated in follow-on funding

“The LUNGevity award has been transformative for my career. I would not be able to conduct (this) clinical trial and do the important data analysis without it. I am particularly grateful for the opportunity to meet the LUNGevity Scientific Advisory Board members, all leaders in the lung cancer field. Their support and comments have been invaluable to my research.”

**JOSH BAUML, MD,** Assistant Professor of Medicine, Hospital of the University of Pennsylvania and CDA recipient
LUNGevity Scientific and Clinical Roundtable Initiative (SCRT)

LUNGevity leads the field in convening thought leaders to improve outcomes for people living with lung cancer by accelerating research and regulatory review to expand access to more effective therapies for patients.

Since 2016, the LUNGevity Scientific and Clinical Roundtable (SCRT) Initiative has used a multi-stakeholder participant model to focus on defining—and achieving—patient-centric, efficient clinical trial and therapy development paradigms for lung cancer.

The Roundtables have developed actionable steps to streamline lung cancer clinical trials and make them more accessible to patients. SCRT meetings engage leaders from the U.S. Food and Drug Administration (FDA), ex-U.S. regulatory agencies, and industry; clinicians; and patients and patient advocates. Working groups have developed recommendations to reduce unnecessary and burdensome adverse event reporting and to eliminate outdated exclusion criteria; focused on improving Patient Reported Outcomes efforts and utility; and created a framework for clinical trial eligibility criteria.

SCRT priorities were modified in 2020 to respond to the impact of the pandemic on lung cancer treatment. The virtual meeting included “lessons learned” about the treatment of cancer patients on clinical trials during the health crisis and updates from working groups on how new regulatory aspects have and will affect the design, conduct, and review of cancer clinical trials. Brought to the forefront by COVID-19 were barriers to broader implementation of decentralized clinical trials and increased diversity of trial populations.

LUNGevity hosted a special listening session with the FDA and patients to address concerns about participating in lung cancer clinical trials in an era of COVID as well as a roundtable with trial sponsors to discuss key elements of clinical trials impacted by COVID: eligibility criteria, statistical analysis, and safety monitoring. Working groups are developing actionable recommendations.

Understanding the Unmet Needs of Cancer Cachexia Patients

Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, physical weakness, lack of energy, and anemia. Cachexia is so destructive that it taps into other sources of energy, namely skeletal muscle and adipose tissue, when the body senses a lack of nutrition.

LUNGevity held a one-day workshop focused on identifying unmet needs in cachexia, including such topics as education and awareness, understanding the patient experience, and endpoint selection. We are continuing to work with partners to advance this field to benefit patients.

Scientific and Clinical Roundtable Publications

Consisting of clinician leaders, members of the FDA, and industry partners, the working groups have focused on several topics identified by the SCRT, including:

2019 Expanding eligibility criteria so that more patients (such as those with a history of prior cancer, brain metastases, etc.) get access to new therapies. Manuscript published in Journal of Thoracic Oncology.

2019 Refining how patient-reported outcomes (PROs) are used in lung cancer clinical trials. Manuscript published in the Journal of Thoracic Oncology.

2020 Removing overly restrictive or outdated eligibility criteria from lung cancer clinical trials. Manuscript titled Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multi-stakeholder Working Group recently accepted at Clinical Lung Cancer.

2020 Developing a list of side effects that are generally “anticipated” to occur among patients with lung cancer and that would therefore not need to be reported individually, to reduce the burden of excessive clinical trial reporting. Manuscript titled Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer recently accepted at Therapeutic Innovation and Regulatory Science.
PATIENT FORCE
LUNGevity’s Patient-Focused Research Center (Patient FoRCe) connects the patient voice with health care professionals, regulators, policymakers, and drug developers to ensure their voices are heard and incorporated into decisions. This changes the paradigm in lung cancer from assumptions about patient preferences to evidence-based conclusions about what patients and caregivers truly value. Through qualitative and quantitative research, Patient FoRCe seeks to uncover gaps in information, misperceptions about patient attitudes, and areas of unmet need. We then incorporate these learnings into the development of policy, treatments, and research protocols.

Project PRIORITY:
Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment study), is a collaboration between LUNGevity and the EGFR Resisters — a patient group dedicated to changing EGFR-positive lung cancer into a manageable chronic disease. Conceptualized by EGFR Resisters co-founders, Anita Figueras, Teri Kennedy, and Ivy Elkins, the goal is to understand unmet needs of their community. It began with an international, longitudinal survey aimed at understanding the diagnostic and treatment journey of EGFR-positive patients. Preliminary results were presented at IASLC’s 20th World Conference on Lung Cancer (WCLC) and the 2019 North America Conference on Lung Cancer (NACLC). This first-of-its-kind study identifies significant unmet needs, including lack of access to both biomarker testing and targeted therapies for the EGFR mutation, and high burden of depression and suicidal thoughts in the community.

Project PEER: Understanding the lung cancer Patient ExperiEnce in the Real-world setting
Project PEER, a multi-year, international study, seeks a better understanding of the patient experience. LUNGevity is proud to collaborate with the US Food and Drug Administration (FDA), offering the agency real-world data on how members of our patient population, particularly those underrepresented in clinical trials, respond to therapies. Project PEER is a collaboration between LUNGevity, the Critical Path Institute (C-Path), the FDA, the European Organization for Research and Treatment of Cancer (EORTC), and Lung Cancer Europe (LuCE) and is the first international study to understand the lung cancer patient experience outside of a clinical trial. Data collected through the study will provide an accurate snapshot of how patients globally are accessing diagnostic and therapeutic modalities, and allow comparison of how patients feel and function on different therapies outside of a clinical trial. This information is critical to driving change in lung cancer research, treatment and policy.
LUNGevity is investing in multiple long-term programs to promote access to comprehensive biomarker testing to patients and healthcare providers.

**LUNGevity’s Take Aim Initiative**

The goal of the Take Aim Initiative is to ensure that all people diagnosed with non-small cell lung cancer have access to comprehensive biomarker testing. This will mean that the right treatment or care plan at the right time is possible for all NSCLC lung cancer patients, both of which require comprehensive biomarker testing as a first step. LUNGevity pursues strategic collaborations to reach this goal, often reaching across cancers to address barriers to testing.

**Key Highlights:** LUNGevity’s Take Aim Initiative focuses on ensuring that all people diagnosed with NSCLC have access to timely, high-quality comprehensive biomarker testing — a key component of precision medicine — at diagnosis and progression/recurrence of their disease. In 2020, LUNGevity augmented its leadership role in this area through several new initiatives.

**Consistent Testing Terminology Working Group**

The use of consistent testing terminology is needed to support all cancer patients. A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners was formed to address patient confusion by identifying and adopting consistent, plain language terms for biomarker and germline genetic testing that are applicable across cancer types.

“Biomarker testing” was selected as the preferred term. An abstract on the Working Group’s recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library.

**Project DIRECT**

LUNGevity is working on a two-year initiative, Project DIRECT (Eliminating Disparities in Lung Cancer Comprehensive Biomarker Testing) to understand the testing and treatment gap in underserved communities, with the ultimate goal of developing patient-centric solutions to close this gap. Project DIRECT is a partnership between LUNGevity and the Association of Community Cancer Centers (ACCC), which will be evaluating these same issues by studying healthcare providers that work with underserved patient communities. Involving HCPs is a critical component of any patient-facing intervention — not only to acquire physician buy-in but also to ensure that the burden of health-seeking behavior is not disproportionately shouldered by a patient.

**Providing a patient advocacy lens to healthcare provider-focused biomarker testing efforts**

LUNGevity is involved in two provider-focused efforts including a nursing education initiative on biomarker testing and a multi-disciplinary team initiative to ensure that biospecimens used in molecular analysis are handled with care to ensure their integrity for accurate and complete comprehensive biomarker testing.

**Patient Education on Biomarker Testing**

An informed patient community is more likely to be empowered to ask a doctor for biomarker testing at diagnosis and progression/recurrence of their disease. LUNGevity developed tip sheets to help newly diagnosed patients ask their doctors about biomarker testing, as well as on how to read their biomarker testing results report.

**Nursing and Nurse Navigator Education Series**

LUNGevity has been working with Clinical Education Concepts, a CME company, to develop biomarker testing education for nurses and other providers. Partners in this effort include Oncology Nursing Society (ONS) Regional Chapters and oncogene patient groups such as EGFR Resisters. An important goal for these sessions is to encourage nurses to collaborate with their multi-disciplinary teams to advocate for comprehensive biomarker testing for their non-small cell lung cancer (NSCLC) patients and to have the appropriate conversations with patients, to educate them about the value of testing and waiting for testing results before making any decisions about their treatment plans.
LUNGevity convened three important meetings to identify the most effective means of overcoming barriers to biomarker testing for patients.

**Pan Tumor Patient Advocacy Best Practices Roundtable**

The Pan Tumor Patient Advocacy Best Practices Roundtable included 10 patient advocacy groups and two professional societies that have expertise in biomarker testing advocacy for their patient and provider communities. Best practices were shared, and discussion followed on how to overcome barriers to biomarker testing and precision medicine. A whitepaper with next steps will be forthcoming.

**Nursing and Nurse Navigator Roundtable**

The Nursing and Nurse Navigator Roundtable included nurses, nurse navigators and social workers who work in academic settings, community oncology clinics, and with underserved and/or rural populations. Participants identified barriers nurses and nurse navigators face when discussing biomarker testing with their advanced stage, non-small cell lung cancer (NSCLC) patients, and offered potential solutions.

**Pre-analytics Precision Medicine Meeting**

LUNGevity partnered with leaders in the pathology space to help create a standardized approach to tissue and blood acquisition, transportation, handling, and processing for all cancers. These steps are commonly referred to as “pre-analytics.”

The delivery of precision medicine is not only dependent on conducting comprehensive biomarker testing, but also reliant on the molecular pathologist having access to high-quality tissue and blood to perform the molecular analysis. With support from LUNGevity, lead pathologist Dr. Carolyn Compton, Arizona State University, convened a meeting of stakeholders in pre-analytics in precision medicine. The two-day meeting was held in Washington, DC with leaders from government, academia, medical societies, industry and advocacy across cancers. This “Do-Tank” is working toward adoption of consistent pre-analytics standards for biospecimens. LUNGevity is proud to have worked on this landmark initiative to create a foundation to enable the promise of precision medicine for all cancer patients.

“I can only imagine the thanks you’re getting for leading this incredible effort. Thank you for letting us be part of this initiative. Your leadership on this is so appreciated and YEAH to LUNGevity for making this happen. Can’t wait to look back in one year and see how our efforts resulted in such change... all for the patient community.”

**DAVE DUBINSKI**, Head of Patient Global Affairs, Blueprint Medicine
STATE-BY-STATE REPORT CARD ON ACCESS TO OPTIMAL CARE IN LUNG CANCER

In February 2020, LUNGevity released the first-ever Lung Cancer Scorecard, which graded individual states on policies that support access to optimal care for lung cancer patients on Medicaid. The report was presented at a Capitol Hill Briefing in Washington, DC attended by policymakers, healthcare providers, patients/survivors, and other members of our community.

The Scorecard evaluates all 50 states on their Medicaid policies that impact access to optimal care for lung cancer patients. To develop the report, we examined the incidence and survival rates of lung cancer in all 50 states. We then correlated state commitment to improving these outcomes by examining state Medicaid coverage policy for clinical care including coverage for lung cancer screening, access to clinical centers of excellence, and routine costs of clinical trials and personalized approach to lung cancer therapy as evidenced by coverage of biomarker testing.

Only four states — Maryland, Minnesota, Oregon, and Washington — received an “A” grade, while 14 states received an “F” grade.

The Lung Cancer Scorecard clearly illustrates the disparities in access to healthcare in the U.S., and establishes a baseline to measure improvements (or lack thereof) in how lung cancer care is delivered. LUNGevity will identify pain points and opportunities in the system that we can address at the State level to improve patient access to optimal care.

The report resides on the website and at www.LungCancerScore.org. An interactive US map offers the ability to find key stats for each state, and scorecard results can be downloaded.

California State Legislation

Following the state legislative briefing in Sacramento, CA on the Promise of Precision Medicine on February 11, 2020, LUNGevity provided extensive feedback on state legislation in California (AB 2640) that proposed to...
eliminate prior authorization for biomarker testing. LUNGevity provided technical expertise on the terminology that was used in the draft and also pulled together feedback from multiple cancer organizations. The legislative staffers were impressed with the level of expertise. The findings from the report cards will help to inform our policy and programmatic work, in particular our work in addressing disparities in access to optimal care at the state level.

**LUNGevity ACTION NETWORK**

In late October, LUNGevity launched the LUNGevity Action Network, a new engagement program that enables lung cancer advocacy at many levels. The Action Network empowers advocates to engage in awareness and policy actions to help drive change and improve lives and outcomes of those affected by the disease.

Lung cancer is a historically stigmatized and underfunded disease. The lung cancer community needs a powerful and unified way to bring about change. Those who sign up to be members of the Action Network will be offered two avenues for action. Through **awareness-related actions**, members can help educate, engage, and empower their community by sharing their personal story, creating and posting important information on social media, and distributing educational materials locally to spread facts and information about lung cancer. Through **policy-related actions**, members can make their voices heard on issues that affect the lung cancer community by taking actions such as writing their congressmen, signing petitions, and commenting on new regulations.
LUNGevity promotes comprehensive biomarker testing and other important education messages to help people with lung cancer play a more active role in their healthcare. Coordinated, long-term campaigns expand the organization’s reach, allowing us to continue to provide information that can improve patient outcomes.

**Inhale for Life: Right Track**

On November 4, 2020 LUNGevity launched its Inhale for Life: Right Track educational campaign. This powerful campaign features video stories of lung cancer survivors and their families and aims to answer the first question of people recently diagnosed with lung cancer: “What do I do now?”

The fourth installment in LUNGevity’s annual Inhale for Life campaign series uses paid and organic social media to educate lung cancer patients and their families about achieving the best outcomes.

The Right Track offers a roadmap for achieving the best possible outcomes in lung cancer treatment and care. Newly diagnosed patients are advised to get on the right track right away — seeing the right team, having the right tests, and getting the right treatment, right from the start.

The Right Track follows The Inhale for Life: Clinical Trials campaign that wrapped in February. The Inhale for Life General awareness PSA ran on NBC-NY programming during the whole month of November for Lung Cancer Awareness Month.

**No One Missed Campaign**

LUNGevity launched a new multi-year, multi-stakeholder campaign that aims to ensure there’s “No One Missed” in receiving comprehensive biomarker testing and a fully informed diagnosis for the best treatment options for each unique NSCLC patient.

The campaign includes a landing page on the LUNGevity website, paid social media, point-of-care materials, guides for caregivers and healthcare professionals and a KOL public relations and social media effort. No One Missed, a uniquely community-led campaign, launched April 2021. LUNGevity is joined by patient groups, medical professional societies such as AONN and IASLC, and industry partners to spread the messaging. Support for No One Missed is provided by founding partner AstraZeneca; founding members Amgen and Genentech; supporting member Pfizer; members AbbVie, Daiichi-Sankyo, Merck, Regeneron, Sanofi Genzyme, Takeda Oncology and ThermoFisher; and supporters EMD Serono, Exact Sciences, Mirati Therapeutics, Neogenomics, Novartis, and Oncocyte.
International Lung Cancer Survivorship Conference (ILCSC)

LUNGevity’s first-ever virtual International Lung Cancer Survivorship Conference was a hit! With 1,445 registrants from 38 countries, it was truly the world’s largest virtual gathering of lung cancer survivors and caregivers.

ILCSC provides a variety of opportunities to connect with other survivors, hear from world-renowned researchers on the latest treatments, and learn about ways to manage lung cancer and the treatment journey. This unique conference, designed by and for people diagnosed with lung cancer and their caregivers, has been described by past attendees as “transformational.”

This year, attendees participated through an online conference center, entering the lobby for information, the auditorium for sessions, an exhibit hall to meet with vendors, and meeting rooms for informal conversations on a variety of special interests.

The virtual format for the traditionally in-person event allowed for even more great expert speakers, sessions, and meetups that would not be possible in person. It also allowed the educational event to be available to more people affected by lung cancer who otherwise might have been restricted by monetary, mobility, or health concerns. LUNGevity has committed to offering a virtual meeting each year focused on education, as well as the in-person event.

Highlights of the conference include:

- An Inspiring keynote by Dr. David Carbone, Director of the James Thoracic Oncology Center, The Ohio State University Wexner Medical Center
- An informative session on lung cancer care in the community setting, in which our experts encouraged anyone to feel comfortable about seeking a second opinion
- A lively session on Sex, Drugs, and Rock & Roll, in which we learned about palliative care, the benefits of musical therapy, and options available for those facing sexual intimacy issues as a result of cancer treatment
- An important conversation on lung cancer and COVID in the African American Community
“The Lunch & Learn was very informative. It was a great event to hear other survivors’ points of view, in order to help my father continue to thrive with lung cancer.”

CHRISTEN G., caregiver

LUNCH & LEARNS
LUNGevity’s Lunch & Learns are interactive educational meetings designed for those affected by lung cancer, including patients, caregivers, and medical professionals and are held across the country in collaboration with local hospitals and lung cancer support groups, particularly in underserved areas. The meetings offer attendees the opportunity to hear from lung cancer experts and learn about survivorship services and resources available through LUNGevity, as well as in their own communities.

LUNGevity’s Lunch & Learn program held four events before the pandemic lockdown in locations that introduced the organization to new communities. Sessions highlight lung cancer treatment options, discuss advances in lung cancer research, provide tips on how to live well with cancer, and share support resources for those living with lung cancer.

EDUCATIONAL MATERIALS
Lung cancer patients and caregivers can find the facts they need through LUNGevity’s comprehensive educational booklets covering all aspects of the disease — from types and stages of lung cancer to testing and treatments. We make it easier to be an informed advocate in your healthcare, and our materials can be printed at home for your convenience.

Many of the LUNGevity educational booklets have been recently translated into Spanish.

In addition, a Spanish version of the Inhale for Life: Biomarker Testing PSA was created and posted on the LUNGevity website and social media.

New booklets in 2020:
• Radiation Therapy
• Small Cell Lung Cancer
NATIONAL CELEBRATION OF HOPE
LUNGevity Foundation held its National Celebration of Hope on October 21, 2020. The virtual event, hosted by WNBC weather anchor Dave Price, brought together business leaders, philanthropists, policymakers, and advocates to celebrate and support the progress of lung cancer research. The funds raised at this year’s event are more important than ever as the coronavirus pandemic has put critical, life-altering lung cancer research at risk by disrupting momentum and impacting progress for those affected by the disease. As part of the evening’s festivities, LUNGevity honored individuals and organizations who have made notable contributions to the lung cancer community.

FACE OF HOPE AWARD recipIEntS

Jill Feldman, Lung Cancer Survivor and Advocate, Co-founder, EGFR Resisters patient group

Frederick P. Smith, MD, FACP
Attending Medical Oncologist, Sibley Memorial Hospital
Clinical Associate Professor, Georgetown University School of Medicine
Clinical Assistant Professor, Johns Hopkins School of Medicine

CHAMPION OF HOPE AWARD FOR VOLUNTEER LEADERSHIP

Kathy Cuddy, Lung cancer advocate
LUNGevity volunteer

FACE OF HOPE AWARD FOR CORPORATE LEADERSHIP

AstraZeneca
Presented to acknowledge the company’s commitment to the health and well-being of lung cancer communities in the US and globally, and for its tireless commitment to support the science that improves lives.

SPECIAL THanks

LUNGevity would like to thank its National Celebration of Hope co-chairs, who helped to transition our spring and fall galas into a moving virtual experience.

Brent Barnhart
Vice President
UBS Private Management

Andre Owens
Partner
WilmerHale
LUNGevity Board Member

Nancy Cohen
Lung Cancer Patient and Advocate (In Memoriam)

Natalie Cohen Smith
Senior Vice President
Consero
Due to COVID-19, LUNGevity was unable to hold community events in Fall 2020. The events team focused on creating a national effort to raise revenue and awareness with participation on the same day. 257 teams, 1,611 participants, and 36 survivors from around the country walked together on October 24. Additionally, Breathe Deep secured 44 sponsors and several corporate teams. The event program took place on Facebook Live featuring top team fundraisers, live music, and Doug Kammerer, Washington DC’s NBC Chief Meteorologist as the emcee. After the program, our participants walked in their neighborhoods and shared photos on LUNGevity’s Facebook and Twitter platforms. Social media enabled the event participants to capture the activity and bring the lung cancer community together despite being socially distanced.

We plan to continue to hold a virtual Breathe Deep event post-pandemic as it enables us to reach constituents and communities that we had not reached before.

LUNGevity created a virtual endurance program to replace the road races canceled this year due to the pandemic. The eRACE Lung Cancer recruited individual runners, groups, and even corporate relay teams to participate in a run of their choice (5K, 10K, Half-Marathon, Marathon, and relay) and challenged them to raise money to support LUNGevity. The participants needed to complete their runs between October 1 and October 17 with a post-race celebration hosted on Facebook Live on October 18. This concept provided an opportunity for all runners of any level to participate and help generate revenue.

eRACE had 24 teams, 234 participants (representing 24 states with two international runners), and 15 survivors and ran a combined 938 miles. Participants posted photos on social media to show when they ran and their results using #eRACELungCancer and #TeamLUNGevity.
“My dog and I are walking most days for LUNGevity! I support LUNGevity because they support me, give me hope and inspire me. I will begin my fourteenth year of surviving lung cancer in January [2021]! “

**SUSAN STRUTZ, 2020 eRace Participant**

<table>
<thead>
<tr>
<th>IMPACT</th>
<th><strong>BREATHE DEEP TOGETHER</strong> <em>(Spring and Fall Events)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAMS</td>
<td>257</td>
</tr>
<tr>
<td>PARTICIPANTS</td>
<td>1611</td>
</tr>
<tr>
<td>SURVIVORS</td>
<td>36</td>
</tr>
<tr>
<td>SPONSORS</td>
<td>44</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMPACT</th>
<th><strong>eRACE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAMS</td>
<td>24</td>
</tr>
<tr>
<td>PARTICIPANTS (REPRESENTING 24 STATES)</td>
<td>234</td>
</tr>
<tr>
<td>SURVIVORS</td>
<td>15</td>
</tr>
<tr>
<td>MILES IN TOTAL</td>
<td>938</td>
</tr>
</tbody>
</table>
In 2020, LUNGevity strengthened its commitment to addressing the unmet needs of all members of the lung cancer community by adding key program management positions, four prestigious board members and two highly regarded Scientific Advisory Board members.

**NEW HIRES**

**Jeanne Regnante** became the first Chief Health Equity and Diversity Officer in March. A longtime healthcare and global patient engagement professional, Jeanne oversees the strategic design, development, management, and communication of key diversity, equity, and inclusivity (DEI)-related policies, programs, and partnerships, and leads initiatives focusing on the social determinants of health. She is involved across the organization’s many initiatives and programs to ensure that LUNGevity is addressing health equity and access issues. Finally, Jeanne is working to expand the Foundation’s programs and services to better serve opportunity populations and ensure that socially and economically underserved populations benefit from optimal care.

**Elizabeth Barksdale, PhD** joined LUNGevity as Director of Regulatory Affairs and Scientific Policy. Libby worked most recently as Assistant Director, Regulatory Science and Policy for AACR, where she collaborated with LUNGevity staff on policy initiatives. She is responsible for guiding LUNGevity’s regulatory affairs as well as managing and implementing the organization’s clinical trial transformation work.

**Bellinda King-Kallimanis, PhD** joined LUNGevity in the position of Director of Patient-Focused Research. Bellinda served most recently as Senior Staff Fellow in the office of Hematology and Oncology products in the Center for Drug Evaluation and Research, Office of New Drugs at the US Food and Drug Administration. She will manage Project PEER and other patient insight studies.

**NEW SCIENTIFIC ADVISORY BOARD MEMBERS**

**Maximillian Diehn, MD, PhD** is the CRK Faculty Scholar and associate professor of radiation oncology at Stanford University School of Medicine. He is also the vice chair of research in the Department of Radiation Oncology as well as the division chief of radiations and cancer biology.

**Christine Lovly, MD, PhD** is an associate professor of medicine at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center as well as co-leader of the Translational Research and Interventional Oncology Program at Vanderbilt-Ingram Cancer Center.

**NEW BOARD MEMBERS**

**William “BJ” Jones**  
*Chief Commercial Officer, Migraine and Common Disease, Biohaven Pharmaceuticals.*  
BJ Jones has over 25 years of commercial experience in the healthcare industry, launching mass market products and leading commercial teams across a variety of therapeutics.

**Michael Kolodziej, MD**  
*Vice President and Chief Innovation Officer, ADVI Health*  
American College of Physicians Fellow.  
As a longtime healthcare advocate, Michael has published and spoken extensively on the topics of for payment reform, personalized medicine, and practice care delivery transformation in oncology.

**Nichelle Stigger**  
*Lung cancer patient and advocate*  
Nichelle’s experience as a patient and her passion as an advocate for women of color will expand the Board’s perspective and strengthen the Foundation’s work of improving outcomes for people with lung cancer.

**Robert Winn, MD**  
*Director, Virginia Commonwealth University Massey Cancer Center*  
Dr. Winn brings years of experience in lung health and specifically lung cancer along with a passion for health equity and diversity that will help the Foundation grow strategically in ways that will have maximum impact on all who are affected by lung cancer.
BOARD OF DIRECTORS

Alexander F. Stern, Chairman
President, Lazard

Tom Galli, Treasurer
Founder, Ingenium Cubed, LLC

Nichelle Stigger, Secretary
Language and Literature Teacher, District 97, Oak Park, IL

Peter Babef
Global Head of Financial Institutions, Citigroup / Global Banking

Lynne Doughtie
Former Chairman and Chief Executive Officer, KPMG LLP

Andrea E. Ferris
President and Chief Executive Officer, LUNGevity Foundation

William “BJ” Jones
Chief Commercial Officer, Migraine and Common Diseases, Biohaven Pharmaceuticals

Jennifer Kashatus
Partner, DLA Piper, LLP

Michael Kolodziej, MD
Senior Advisor, ADVI Health

Michael Marquis
President, Vogue International, a Johnson & Johnson Company

Andre Owens
Partner, WilmerHale

Michael Parisi
Chief Executive Officer, Guidemark Health

Charles Rudin, MD, PhD, Chair, Scientific Advisory Board
Professor and Chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center

Andrew Stern
Founder and Managing Partner, Aurify Brands

Paul G. Stern
Former Presiding Director, The Dow Chemical Company

Former Director, Whirlpool Corporation

Robert Winn, MD
Director, Virginia Commonwealth University Massey Cancer Center

*deceased

SCIENTIFIC ADVISORY BOARD

Charles M. Rudin, MD, PhD, Chairman
Memorial Sloan Kettering Cancer Center

Scott J. Antonia, MD, PhD
Duke Cancer Institute

Philip D. Bonomi, MD
Rush University Medical Center

Julie R. Brahmer, MD
Johns Hopkins Sidney Kimmel Cancer Center

Lauren Averett Byers, MD
The University of Texas MD Anderson Cancer Center

David P. Carbone, MD, PhD
The Ohio State University

Suzanne E. Dahlberg, PhD
Boston Children’s Hospital

Maximilian Diehn, MD, PhD
Stanford University School of Medicine

Jessica S. Donington, MD, MScR
University of Chicago Medicine

Steven M. Dubinett, MD
David Geffen School of Medicine at UCLA

Patrick Forde, MD, BCh
Johns Hopkins Sidney Kimmel Cancer Center

Edward W. Gabrielson, MD
Johns Hopkins University School of Medicine

Edward B. Garon, MD
David Geffen School of Medicine at UCLA

Jonsson Comprehensive Cancer Center

John V. Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center

Robert L. Keith, MD
University of Colorado Denver Rocky Mountain Regional VAMC

Benjamin P. Levy, MD
Johns Hopkins School of Medicine

Christine Lovly, MD, PhD
Vanderbilt University Medical Center

Pierre P. Massion, MD*
Vanderbilt-Ingram Cancer Center

Drew Moghanaki, MD, PhD
UCLA Department of Radiation Oncology

Greater Los Angeles Veterans Affairs Medical Center

Paul Paik, MD
Memorial Sloan Kettering Cancer Center

Lawrence H. Schwartz, MD
NewYork-Presbyterian Hospital/Columbia University Medical Center

Lecia V. Sequist, MD, MPH
Harvard Medical School Massachusetts General Hospital Cancer Center

Alice T. Shaw, MD, PhD
Novartis Institutes for BioMedical Research

Steven J. Skates, PhD
Harvard Medical School Massachusetts General Hospital

Avrum E. Spira, MD, MSci
Boston University Lung Cancer Initiative, Johnson & Johnson

Anil Vachani, MD
University of Pennsylvania
BETHESDA OFFICE
6917 ARLINGTON ROAD, SUITE 352, BETHESDA, MD 20814
PH: 240.454.3100   F: 240.497.0034

CHICAGO OFFICE
228 S. WABASH AVENUE, SUITE 700, CHICAGO, IL 60604
PH: 312.407.6100   F: 312.464.0737

EMAIL: INFO@LUNGEVITY.ORG

www.LUNGevity.org